RPC1063 — Competitive Intelligence Brief

RPC1063 (RPC1063) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P receptor modulator. Area: Oncology.

phase 3 S1P receptor modulator S1P1 Oncology Small molecule

Target snapshot

RPC1063 (RPC1063) — Celgene. RPC1063 is a sphingosine 1-phosphate receptor modulator.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RPC1063 TARGET	RPC1063	Celgene	phase 3	S1P receptor modulator	S1P1
Group S+T	Group S+T	Huazhong University of Science and Technology	marketed	S1P receptor modulator	S1P1
fingolimob (FTY)	fingolimob (FTY)	University Hospital, Clermont-Ferrand	marketed	Sphingosine-1-phosphate receptor modulator	S1P1 receptor (sphingosine-1-phosphate receptor 1)
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
TVAV-008	TVAV-008	Grand Theravac Life Sciences (Nanjing) Co., Ltd.	phase 3	S1P1 receptor modulator	S1P1
JYB1904	JYB1904	Jemincare	phase 3	S1P1 receptor antagonist	S1P1
Elizaria®	Elizaria®	AO GENERIUM	phase 3	S1P receptor modulator	S1P1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P receptor modulator class)

1. Promius Pharma, LLC · 2 drugs in this class
2. Nobelpharma · 2 drugs in this class
3. Bausch & Lomb Incorporated · 1 drug in this class
4. Biogen · 1 drug in this class
5. Celgene · 1 drug in this class
6. Geropharm · 1 drug in this class
7. GlaxoSmithKline · 1 drug in this class
8. Hoffmann-La Roche · 1 drug in this class
9. Huazhong University of Science and Technology · 1 drug in this class
10. Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class